Drug Profile
Research programme: central nervous system disorder therapeutics - Sumitomo Pharma America
Alternative Names: CNS disorder therapeutics - Sumitomo Pharma AmericaLatest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Sunovion Pharmaceuticals
- Developer Sumitomo Pharma America
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in CNS-disorders in USA
- 13 Aug 2013 Early research in CNS disorders in USA (unspecified route)